TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04351607

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oleovital® Eisen Forte
Description: 60 mg daily oral Supplementation for 3 to 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oleovital® Eisen Forte
Description: 60 mg daily oral Supplementation for 3 to 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleovital® Eisen Forte
Description: 60 mg daily oral Supplementation for 3 to 6 weeks
Study: NCT02758600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise rehabilitation protocol
Description: Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise rehabilitation protocol
Description: Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
Study: NCT02388464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (low dose) administered as single intravenous infusion over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (high dose) administered as single intravenous infusion over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
Study: NCT03496064

Intervention type: OTHER
Intervention: Successful reperfusion
Description: Defined as modified Thrombolysis in Cerebral Infarction 2b/3

Intervention type: OTHER
Intervention: Successful reperfusion
Description: Defined as modified Thrombolysis in Cerebral Infarction 2b/3
Study: NCT02882438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infected group
Description: Ginkgo Biloba in different dosage forms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: placebo without Ginkgo Biloba
Study: NCT02526953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycins
Description: 10 mg/m2, IV, on day 1. Number of infusions: 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycins
Description: 12 mg/m2, IV, on day 1. Number of infusions: 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
Study: NCT01294137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilatory polygraphy
Study: NCT01074476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: 750mg glucosamine sulphate (oral tablets), twice per day for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, twice per day for 3 months
Study: NCT01872585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization based therapy
Description: 12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
Study: NCT02279368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Counselling and safeguarding
Study: NCT03964168

Intervention type: DRUG
Intervention: Biologic Agent
Description: Patients who discontinued a bioloic agent
Study: NCT02972346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
Study: NCT01564212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard airflow with forced air warming.
Description: Subjects will lie on operating room bed with standard airflow and forced air warming.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laminar airflow with surgical drapes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laminar airflow with forced air warming
Description: Subjects will lie on operating room bed with laminar airflow and forced air warming.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard airflow with surgical drapes
Description: Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
Study: NCT02777359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the transcatheter closure of PFO
Description: the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
Study: NCT02041390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reminder
Description: After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional reminder
Description: After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
Study: NCT02515968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT01491061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, 1,000 mg twice 12 hours apart prior to PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: os, two doses 12 hours apart prior to PCI
Study: NCT03617601

Intervention type: DIAGNOSTIC_TEST
Intervention: MET
Description: Testing of the metabolic equivalent of task before aortic procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: MET
Description: Testing of the metabolic equivalent of task before aortic procedure
Study: NCT03097523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Thigh Cuff
Description: The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
Study: NCT00162214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib + Ketoconazole
Description: Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
Study: NCT03107858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Study: NCT03582046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Perfusion Pressure (APP)
Description: Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mean Arterial Pressure (MAP)
Description: Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
Study: NCT02445105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autism Navigator Enhanced Practice
Description: Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Engagement plus Autism Navigator
Description: Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
Study: NCT04628702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tablet training
Description: 1.5 year training period
Study: NCT02880228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03162796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
Study: NCT00303784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: 3.6mg implant, in pre-filled syringe
Study: NCT03162796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study: NCT00303784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Study: NCT02376231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for EOC with trial (PJ) device (PlasmaJet)
Description: Debulking surgery for EOC using PJ device
Study: NCT03196102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTI
Description: Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette smoking military tailored pamphlet
Description: The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette smoking military tailored pamphlet
Description: The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation intervention
Description: This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
Study: NCT04380116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soberlink
Description: Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
Study: NCT03722966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine Replacement Therapy (NRT)
Description: Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
Study: NCT01386567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsules oral 1x a day~1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim (topical testosterone)
Description: topical~1 tube~1x a day~1 year
Study: NCT04063644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vis Glyc Neo
Description: 1 drop in each eye, three times a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution
Description: 1 drop in each eye, three times a day.
Study: NCT00568204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mexyn-A
Description: Atomised topical self-chilled pressurised spray
Study: NCT04466787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spectral Photon Counting Computed Tomography (SPCCT)
Description: The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dual Energy CT (DECT)
Description: The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips
Study: NCT03538275

Intervention type: OTHER
Intervention: Monitoring test
Description: Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.

Intervention type: OTHER
Intervention: Monitoring test
Description: Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.

Intervention type: OTHER
Intervention: Monitoring test
Description: Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
Study: NCT02540876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilorasertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00653094

Intervention type: DEVICE
Group type: OTHER
Intervention: Halevy kit
Description: the use of Halevy kit in Crohn patients with Fistulas
Study: NCT01240304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.